Nisa Investment Advisors LLC Buys New Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)

Nisa Investment Advisors LLC bought a new stake in C4 Therapeutics, Inc. (NASDAQ:CCCC) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 690 shares of the company’s stock, valued at approximately $26,000.

Other institutional investors have also recently modified their holdings of the company. O Shaughnessy Asset Management LLC bought a new stake in C4 Therapeutics in the 1st quarter valued at about $38,000. E Fund Management Co. Ltd. bought a new stake in C4 Therapeutics during the 1st quarter worth approximately $72,000. SG Americas Securities LLC bought a new stake in C4 Therapeutics during the 1st quarter worth approximately $147,000. Jane Street Group LLC bought a new stake in C4 Therapeutics during the 1st quarter worth approximately $211,000. Finally, Meristem Family Wealth LLC bought a new stake in C4 Therapeutics during the 2nd quarter worth approximately $227,000. 65.94% of the stock is owned by institutional investors and hedge funds.

A number of analysts have commented on the company. Brookline Capital Acquisition assumed coverage on C4 Therapeutics in a report on Thursday, June 24th. They set a “buy” rating and a $54.00 price objective for the company. BMO Capital Markets boosted their price objective on C4 Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a report on Tuesday, June 22nd. HC Wainwright assumed coverage on C4 Therapeutics in a report on Friday, June 4th. They set a “buy” rating and a $63.00 price objective for the company. Finally, Brookline Capital Management reissued a “buy” rating on shares of C4 Therapeutics in a report on Friday, June 25th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, C4 Therapeutics presently has an average rating of “Buy” and an average price target of $51.50.

In related news, insider Adam Crystal sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, July 1st. The stock was sold at an average price of $37.98, for a total value of $569,700.00. Following the transaction, the insider now owns 15,000 shares in the company, valued at $569,700. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Malcolm Salter sold 755 shares of the company’s stock in a transaction that occurred on Friday, July 16th. The shares were sold at an average price of $37.37, for a total value of $28,214.35. Following the completion of the transaction, the director now owns 14,427 shares in the company, valued at approximately $539,136.99. The disclosure for this sale can be found here. In the last quarter, insiders sold 126,110 shares of company stock worth $5,814,242. 21.04% of the stock is owned by company insiders.

Shares of NASDAQ CCCC opened at $48.67 on Tuesday. C4 Therapeutics, Inc. has a twelve month low of $22.40 and a twelve month high of $50.58. The stock’s 50 day moving average price is $42.38 and its 200-day moving average price is $38.90. The company has a market capitalization of $2.36 billion and a PE ratio of -8.35. The company has a quick ratio of 10.81, a current ratio of 10.81 and a debt-to-equity ratio of 0.02.

C4 Therapeutics (NASDAQ:CCCC) last announced its earnings results on Tuesday, August 10th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.08. C4 Therapeutics had a negative return on equity of 43.32% and a negative net margin of 257.05%. The firm had revenue of $9.78 million for the quarter, compared to the consensus estimate of $7.45 million. As a group, research analysts expect that C4 Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.

Further Reading: Dual Listing

Want to see what other hedge funds are holding CCCC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C4 Therapeutics, Inc. (NASDAQ:CCCC).

Institutional Ownership by Quarter for C4 Therapeutics (NASDAQ:CCCC)

Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.